Furthermore, numerous perfectly recognized adverse prognostic markers, like U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, misplaced their negative influence in individuals treated with VO. The one aspect that remained predictive of the shorter progression-free survival With this cohort of suffer